白介素17参与脂肪性肝病及其他肝病发病机制的研究进展  

Role of interleukin 17 in fatty liver disease and other liver diseases

作　　者：赵钰鑫[1] 琚坚[1] 王伟[2] 叶江锋 

机构地区：[1]昆明医科大学第二附属医院特需病房科,云南省昆明市650101 [2]昆明医科大学第二附属医院特需病房急诊科,云南省昆明市650101

出　　处：《世界华人消化杂志》2015年第36期5790-5796,共7页World Chinese Journal of Digestology

基　　金：云南省卫生科技计划基金资助项目;No.2012WS0091~~

摘　　要：脂肪性肝病(fatty liver disease,FLD)是由多种原因引起肝脏的脂肪代谢功能发生障碍,脂类物质的平衡失调,致使肝细胞内脂肪蓄积过多的一种病理变化.近年来我国FLD的检出率逐年升高,且发病年龄也在提前,这不得不引起我们高度重视.而关于FLD的病因目前尚未完全明确,对于其治疗大多采用对症治疗为主.在近年研究中发现白介素17(interleukin 17,IL-17)不仅参与多种疾病的发病机制,如自身免疫性疾病、炎症性疾病、恶性肿瘤,同时相关研究已证实了IL-17通过胰岛素抵抗、激活肝内某些重要通路、介导某些炎症因等机制参与了FLD及其他相关肝病的发病过程,本文就IL-17参与F L D及其他肝病发病机制的研究进展作一综述.Fatty liver disease is a lipid metabolism disorder in the liver, with a variety of etiologies which result in the accumulation of fat in the liver. The pathogenesis of fatty liver disease is still unclear and symptomatic treatment is the main method. In recent years, the incidence of fatty liver disease in China is increasing year by year, and the age of onset becomes younger. Recent studies suggest that interleukin 17 （IL-17） is involved not only in the pathogenesis of various diseases, such as autoimmune diseases, inflammatory diseases, and malignant tumors, but also in fatty liver and other liver diseases through inducing insulin resistance, activating some important pathways in the liver, mediating some inflammatory factors and so on. This paper will review the role of IL-17 in fatty liver disease and other liver diseases.

关 键 词：白介素17 脂肪肝 发病机制 

分 类 号：R575.5[医药卫生—消化系统]